<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03019029</url>
  </required_header>
  <id_info>
    <org_study_id>16-006798</org_study_id>
    <nct_id>NCT03019029</nct_id>
  </id_info>
  <brief_title>Diagnostic Utility of F-18 Florbetapir PET/MR in Peripheral Nerve Amyloidosis</brief_title>
  <official_title>Diagnostic Utility of F-18 Florbetapir PET/MR in Peripheral Nerve Amyloidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this study will be to examine the diagnostic utility of 18-F Florbetapir
      PET/MR (Positron Emission Tomography/Magnetic Resonance) in imaging patients with
      pathologically-confirmed systemic amyloidosis involving the peripheral nerves and compare
      these results to non-amyloid diseased controls.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with pathologically proven amyloidosis involving the peripheral nervous system will
      undergo 18-F Florbetapir PET/MR on a GE (General Electric Healthcare) SIGNA PET/MR scanner. A
      control arm comprised of patients with pathologically-confirmed non-amyloid causes of
      peripheral neuropathy will also undergo 18-F Florbetapir PET/MR scanning. all images will be
      reviewed for peripheral nerve uptake.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">March 13, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Participants with biopsy proven peripheral nerve amyloidosis will undergo an F-18 Florbetapir PET/MR scan</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Locations of peripheral nerve 18-F Florbetapir uptake</measure>
    <time_frame>50-120 minutes post injection</time_frame>
    <description>Standardized uptake value (SUV)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pattern of F-18 Florbetapir uptake (Heterogeneous vs. Homogeneous, focal vs. diffuse)</measure>
    <time_frame>50-120 minutes post injection</time_frame>
    <description>Heterogeneous vs. Homogeneous, focal vs. diffuse. This is a categorical variable. There is not a quantitative or semi-quantitative scale that is appropriate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>T1 and T2 characteristics (Hypointense, isointense or hyperintense relative to skeletal muscle)</measure>
    <time_frame>50-120 minutes post injection</time_frame>
    <description>Hypointense, isointense or hyperintense relative to skeletal muscle. This is a categorical variable. There is not a quantitative or semi-quantitative scale that is appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morphologic changes</measure>
    <time_frame>50-120 minutes post injection</time_frame>
    <description>Presence or absence of neural enlargement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pattern of contrast enhancement (Solid, heterogeneous or peripheral enhancement)</measure>
    <time_frame>50-120 minutes post injection</time_frame>
    <description>Solid, heterogeneous or peripheral enhancement. This is a categorical variable. There is not a quantitative or semi-quantitative scale that is appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional sites of 18-F Florbetapir uptake</measure>
    <time_frame>50-120 minutes post injection</time_frame>
    <description>i.e. cardiac myocardium, skeletal muscle, bone marrow</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Amyloidosis</condition>
  <arm_group>
    <arm_group_label>Peripheral nerve amyloidosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with pathologically-confirmed peripheral nerve amyloidosis will undergo 18-F Florbetapir PET/MR scan on a GE SIGNA PET/MR scanner.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>18-F Florbetapir PET/MR scan</intervention_name>
    <description>18-F Florbetapir PET/MR scan, PET/MR on a GE SIGNA PET/MR scanner</description>
    <arm_group_label>Peripheral nerve amyloidosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults: 18-100

          -  Pathologically-confirmed peripheral nerve amyloidosis or pathologically-confirmed
             non-amyloid causes of peripheral neuropathy

        Exclusion Criteria:

          -  Metallic devices that are not MR safe (cardiac pacers, stents, aneurysm coils, etc.)

          -  Claustrophobia

          -  BMI over 38
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen M Broski</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2017</study_first_submitted>
  <study_first_submitted_qc>January 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2017</study_first_posted>
  <last_update_submitted>July 13, 2017</last_update_submitted>
  <last_update_submitted_qc>July 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Stephen M. Broski</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Peripheral Nerve Amyloidosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

